Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer

Mingzhang Gao, Min Wang, Kathy Miller, Qi-Huang Zheng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The enzyme cyclooxygenase-2 (COX-2) is overexpressed in a variety of malignant tumors. This study was designed to develop new radiotracers for imaging of COX-2 in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled celecoxib derivatives, [ 11C]4a-c and [ 11C]8a-d, were prepared by O-[ 11C] methylation of their corresponding precursors using [ 11C]CH 3OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 52 ± 2% (n = 5) and 57 ± 3% (n = 5) radiochemical yields based on [ 11C]CO 2 and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5). The IC 50 values to block COX-2 for known compounds celecoxib (4d), 4a and 4c were 40, 290 and 8 nM, respectively, and preliminary findings from in vitro biological assay indicated that the synthesized new compounds 4b and 8a-d display similar strong inhibitory effectiveness in the MDA-MB-435 human cancer cell line in comparison with the parent compound 4d. These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer.

Original languageEnglish
Pages (from-to)4760-4767
Number of pages8
JournalEuropean Journal of Medicinal Chemistry
Volume46
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Celecoxib
Positron emission tomography
Cyclooxygenase 2
Positron-Emission Tomography
Carbon
Derivatives
Imaging techniques
Neoplasms
Methylation
Solid Phase Extraction
Carbon Monoxide
In Vitro Techniques
Biological Assay
Tumors
Assays

Keywords

  • Cancer imaging
  • Carbon-11-labeled celecoxib derivatives
  • Cyclooxygenase-2 (COX-2)
  • Positron emission tomography (PET)
  • Radiotracers

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

@article{5b639a19aa0048ee893e1218395cd8c0,
title = "Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer",
abstract = "The enzyme cyclooxygenase-2 (COX-2) is overexpressed in a variety of malignant tumors. This study was designed to develop new radiotracers for imaging of COX-2 in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled celecoxib derivatives, [ 11C]4a-c and [ 11C]8a-d, were prepared by O-[ 11C] methylation of their corresponding precursors using [ 11C]CH 3OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 52 ± 2{\%} (n = 5) and 57 ± 3{\%} (n = 5) radiochemical yields based on [ 11C]CO 2 and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the radiochemical purity was >99{\%}, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5). The IC 50 values to block COX-2 for known compounds celecoxib (4d), 4a and 4c were 40, 290 and 8 nM, respectively, and preliminary findings from in vitro biological assay indicated that the synthesized new compounds 4b and 8a-d display similar strong inhibitory effectiveness in the MDA-MB-435 human cancer cell line in comparison with the parent compound 4d. These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer.",
keywords = "Cancer imaging, Carbon-11-labeled celecoxib derivatives, Cyclooxygenase-2 (COX-2), Positron emission tomography (PET), Radiotracers",
author = "Mingzhang Gao and Min Wang and Kathy Miller and Qi-Huang Zheng",
year = "2011",
month = "9",
doi = "10.1016/j.ejmech.2011.05.024",
language = "English",
volume = "46",
pages = "4760--4767",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",
number = "9",

}

TY - JOUR

T1 - Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer

AU - Gao, Mingzhang

AU - Wang, Min

AU - Miller, Kathy

AU - Zheng, Qi-Huang

PY - 2011/9

Y1 - 2011/9

N2 - The enzyme cyclooxygenase-2 (COX-2) is overexpressed in a variety of malignant tumors. This study was designed to develop new radiotracers for imaging of COX-2 in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled celecoxib derivatives, [ 11C]4a-c and [ 11C]8a-d, were prepared by O-[ 11C] methylation of their corresponding precursors using [ 11C]CH 3OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 52 ± 2% (n = 5) and 57 ± 3% (n = 5) radiochemical yields based on [ 11C]CO 2 and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5). The IC 50 values to block COX-2 for known compounds celecoxib (4d), 4a and 4c were 40, 290 and 8 nM, respectively, and preliminary findings from in vitro biological assay indicated that the synthesized new compounds 4b and 8a-d display similar strong inhibitory effectiveness in the MDA-MB-435 human cancer cell line in comparison with the parent compound 4d. These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer.

AB - The enzyme cyclooxygenase-2 (COX-2) is overexpressed in a variety of malignant tumors. This study was designed to develop new radiotracers for imaging of COX-2 in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled celecoxib derivatives, [ 11C]4a-c and [ 11C]8a-d, were prepared by O-[ 11C] methylation of their corresponding precursors using [ 11C]CH 3OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 52 ± 2% (n = 5) and 57 ± 3% (n = 5) radiochemical yields based on [ 11C]CO 2 and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5). The IC 50 values to block COX-2 for known compounds celecoxib (4d), 4a and 4c were 40, 290 and 8 nM, respectively, and preliminary findings from in vitro biological assay indicated that the synthesized new compounds 4b and 8a-d display similar strong inhibitory effectiveness in the MDA-MB-435 human cancer cell line in comparison with the parent compound 4d. These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer.

KW - Cancer imaging

KW - Carbon-11-labeled celecoxib derivatives

KW - Cyclooxygenase-2 (COX-2)

KW - Positron emission tomography (PET)

KW - Radiotracers

UR - http://www.scopus.com/inward/record.url?scp=80052920865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052920865&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2011.05.024

DO - 10.1016/j.ejmech.2011.05.024

M3 - Article

VL - 46

SP - 4760

EP - 4767

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

IS - 9

ER -